Shira Cohen Selected Research

CF101

9/2016	The A3 adenosine receptor (A3AR): therapeutic target and predictive biological marker in rheumatoid arthritis.
1/2016	Treatment of Plaque-Type Psoriasis With Oral CF101: Data from a Phase II/III Multicenter, Randomized, Controlled Trial.
6/2013	Targeting the A3 adenosine receptor for glaucoma treatment (review).
11/2011	Inhibition of experimental auto-immune uveitis by the A3 adenosine receptor agonist CF101.
1/2008	Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial.
10/2007	The anti-inflammatory effect of A3 adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shira Cohen Research Topics

Disease

6	Neoplasms (Cancer) 10/2020 - 01/2013
5	Arthritis (Polyarthritis) 09/2016 - 01/2006
4	Rheumatoid Arthritis 09/2016 - 01/2007
3	Inflammation (Inflammations) 12/2019 - 10/2007
3	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2018 - 01/2016
2	Reperfusion Injury 12/2019 - 11/2016
1	Infections 11/2022
1	COVID-19 11/2022
1	Erectile Dysfunction 10/2022
1	Communicable Diseases (Infectious Diseases) 10/2021
1	Prostatic Neoplasms (Prostate Cancer) 01/2020
1	Fatty Liver 12/2019
1	Fibrosis (Cirrhosis) 12/2019
1	Non-alcoholic Fatty Liver Disease 12/2019
1	Peritonitis 01/2019
1	Chronic Kidney Failure (Chronic Renal Failure) 01/2019
1	Cytokine Release Syndrome 01/2019
1	Necrosis 11/2016
1	Crohn Disease (Crohn's Disease) 09/2016
1	Osteoarthritis 01/2014
1	Dry Eye Syndromes (Dry Eye Syndrome) 06/2013
1	Glaucoma 06/2013
1	Hepatocellular Carcinoma (Hepatoma) 01/2013
1	Uveitis 11/2011
1	Nausea 01/2008
1	Headache (Headaches) 01/2008
1	Exanthema (Rash) 01/2008

Drug/Important Bio-Agent (IBA)

10	Purinergic P1 Receptors (Adenosine Receptor)IBA 10/2022 - 01/2007
6	CF101IBA 09/2016 - 10/2007
3	Proteins (Proteins, Gene)FDA Link 09/2016 - 01/2006
2	AntigensIBA 01/2020 - 11/2011
2	Biomarkers (Surrogate Marker)IBA 01/2019 - 09/2016
2	CollagenIBA 09/2016 - 10/2007
2	Adenosine (Adenocard)FDA LinkGeneric 01/2014 - 01/2008
2	N(6)- (3- iodobenzyl)- 5'- N- methylcarboxamidoadenosineIBA 10/2007 - 01/2006
1	Insulin (Novolin)FDA Link 11/2022
1	Growth Hormone (Somatotropin)IBA 11/2022
1	Apomorphine FDA Link 10/2022
1	Streptozocin (Streptozotocin)FDA Link 10/2022
1	RNA (Ribonucleic Acid)IBA 10/2021
1	Phosphotransferases (Kinase)IBA 10/2020
1	tyrosine receptor (receptor, tyrosine)IBA 10/2020
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2020
1	Single-Domain AntibodiesIBA 01/2020
1	nasIBA 12/2019
1	Alanine (L-Alanine)FDA Link 12/2019
1	CarbonIBA 12/2019
1	Protective AgentsIBA 12/2019
1	LeptinIBA 12/2019
1	AdiponectinIBA 12/2019
1	Pancreatic Ribonuclease (Ribonuclease A)IBA 01/2019
1	Eosinophil Cationic ProteinIBA 01/2019
1	Ribonuclease 7IBA 01/2019
1	Antimicrobial PeptidesIBA 01/2019
1	Ribonucleases (Ribonuclease)IBA 01/2019
1	Interleukin-17 (Interleukin 17)IBA 01/2018
1	Interleukin-23 (Interleukin 23)IBA 01/2018
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 11/2016
1	CytokinesIBA 11/2016
1	TropomyosinIBA 09/2016
1	Adenosine A3 ReceptorIBA 01/2016
1	Concanavalin AIBA 01/2014
1	N- (3,4- dichlorophenyl)- 2- cyclohexyl- 1H- imidazo(4,5- c)quinolin- 4- amineIBA 01/2014
1	interstitial retinol-binding proteinIBA 11/2011
1	Retinaldehyde (Retinal)IBA 11/2011
1	Cell Surface ReceptorsIBA 01/2008
1	Purinergic P1 Receptor AgonistsIBA 10/2007
1	Methotrexate (Mexate)FDA LinkGeneric 10/2007
1	NF-kappa B (NF-kB)IBA 01/2007
1	MitogensIBA 01/2007

Therapy/Procedure

3	Therapeutics 11/2022 - 10/2007
1	Drug Therapy (Chemotherapy) 12/2019
1	Immunotherapy 01/2019
1	Renal Replacement Therapy (Therapies, Renal Replacement) 01/2019
1	Peritoneal Dialysis 01/2019
1	Hepatectomy 11/2016
1	Oral Administration 06/2013